Federated Hermes, Inc. Gracell Biotechnologies Inc. Transaction History

Federated Hermes, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.65 - $14.9 $56,500 - $149,000	-10,000 Reduced 0.76%	1,298,578 $7.84 Million
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $1.22 Million - $1.82 Million	122,689 Added 10.35%	1,308,578 $18.2 Million
Q2 2021 Aug 16, 2021	SELL	$9.75 - $18.42 $49,003 - $92,578	-5,026 Reduced 0.42%	1,185,889 $15.4 Million
Q1 2021 May 13, 2021	BUY	$14.7 - $30.57 $17.5 Million - $36.4 Million	1,190,915 New	1,190,915 $18.3 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.